ResBiotic Pharma is harnessing the power of live biotherapeutics (LBPs) to develop breakthrough medicines specifically engineered to treat chronic lung disease.
Lung Health Starts Here
RB1000 is a pre-clinical phase LBP-based therapeutic for COPD.
RB2000 is a pre-clinical phase LBP-based therapy for Bronchopulmonary Dysplasia (BPD).
RB3000 is a pre-clinical phase LBP-based therapeutic for the treatment of Idiopathic Pulmonary Fibrosis and potentially other chronic lung diseases.